Form 4: Nautilus Biotechnology Executive Exercises and Sells Stock Options

Mary E. Godwin, Senior VP of Operations at Nautilus Biotechnology, exercised stock options and sold the resulting shares on September 17, 2024.

Summary

• On September 17, 2024, Mary E. Godwin, Senior VP of Operations at Nautilus Biotechnology, exercised stock options to acquire 35,000 shares of common stock at a price of $0.46 per share.
• Simultaneously, Godwin sold 35,000 shares of common stock at a weighted average price of $2.8534, with individual sales ranging from $2.80 to $2.99.
• Following these transactions, Godwin no longer directly owns any common stock but retains derivative securities in the form of stock options for 400,368 shares.
• The stock options vest over time, contingent on Godwin's continued service as a 'Service Provider' as defined in the company's equity incentive plan, with a vesting commencement date of January 21, 2020.

Sentiment

Score: 5

Explanation: This is a routine Form 4 filing, indicating an executive exercising and selling stock options. It doesn't inherently signal positive or negative sentiment, but rather reflects personal financial decisions.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track management's sentiment and actions regarding their company's stock.

Stakeholder Impact

• Shareholders may interpret the sale of shares by a company executive as a neutral or slightly negative signal, depending on the context and the executive's overall holdings.

Key Dates